Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Generic Market Primed For Growth, But Distribution And Manufacturing Barriers Remain

This article was originally published in PharmAsia News

Executive Summary

Substantial patent expirations in the next few years and government incentives for generic use make Japan's generic market ideal for midterm growth, but stringent API standards and complex distribution channels have left some foreign firms in a difficult spot.

You may also be interested in...



MHLW Relied On EU and U.S. For Actos Safety Data, But Newly Funded Health Records Database Will Boost Japan's Pharmacovigilance

TOKYO - Japan's Ministry of Health, Labor and Welfare followed the lead of EMA and U.S. FDA and requested Takeda Pharmaceutical Co. Ltd. to change labeling for Actos (pioglitazone) to reflect safety concerns about the risk of bladder cancer. MHLW had to rely on epidemiological data compiled by EMA, but MHLW's safety division hopes new funding from the government will help build an electronic health records database to conduct similar pharmacovigilance epidemiology studies for the Japanese market

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?

Astellas Regains Japan Losses With Xtandi Expansion

Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.

Topics

Related Companies

UsernamePublicRestriction

Register

SC082114

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel